The large majority of drugs on the market today are small molecules and most are delivered orally. Small molecule drugs are part of what Syncona calls, the “First Wave” of technologies in healthcare and are dominated by large pharmaceutical companies.
value of portfolio
Syncona Board seats
*Unless stated all financials at 30 June 2021